晚期前列腺癌的治疗
Treatment of Advanced Prostate Cancer.
作者信息
Thomas Theodore S, Pachynski Russell K
机构信息
Theodore S. Thomas, MD, MPHS, is a staff Oncologist, St. Louis VA Medical Center, St. Louis, Missouri.
Russell K. Pachynski, MD, is Assistant Professor, Division of Oncology, Washington, University School of Medicine, St. Louis, Missouri.
出版信息
Mo Med. 2018 Mar-Apr;115(2):156-161.
Abstract
Advanced prostate cancer is a heterogenous disease with multiple treatment options. Patients with advanced disease are stratified based evidence of metastasis and sensitivity to hormone therapy. Men with hormone sensitive disease are treated with androgen deprivation therapy and possibly chemotherapy. The treatment options for men with castrate resistant disease are rapidly evolving with multiple recently approved treatment options. Determining the proper sequence and combination of these therapies remains a work in progress.
摘要
晚期前列腺癌是一种具有多种治疗选择的异质性疾病。晚期疾病患者根据转移证据和对激素治疗的敏感性进行分层。激素敏感型疾病的男性患者接受雄激素剥夺治疗，可能还会接受化疗。去势抵抗性疾病男性患者的治疗选择正在迅速发展，最近有多种获批的治疗方案。确定这些治疗方法的正确顺序和组合仍在不断探索中。
相似文献
1
Treatment of Advanced Prostate Cancer.晚期前列腺癌的治疗
Mo Med. 2018 Mar-Apr;115(2):156-161.
2
Metastatic castrate-resistant prostate cancer, dawn of a new age of management.转移性去势抵抗性前列腺癌，管理新时代的曙光。
BJU Int. 2013 Mar;111(3):E9-E10. doi: 10.1111/bju.12020_3.
3
Role of radiation and androgen deprivation therapy for advanced prostate cancer.放疗和雄激素剥夺疗法在晚期前列腺癌治疗中的作用。
Curr Probl Cancer. 2015 Jan-Feb;39(1):41-7. doi: 10.1016/j.currproblcancer.2014.11.007. Epub 2014 Nov 25.
4
Medical therapy of prostate cancer. A review.前列腺癌的医学治疗。综述。
Minerva Urol Nefrol. 2005 Jun;57(2):71-84.
5
A re-assessment of the role of combined androgen blockade for advanced prostate cancer.对联合雄激素阻断疗法在晚期前列腺癌治疗中作用的重新评估。
BJU Int. 2004 Jun;93(9):1177-82. doi: 10.1111/j.1464-410x.2004.04803.x.
6
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌：化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
7
Secondary hormonal therapy for prostate cancer: what lies on the horizon?前列腺癌的二线激素治疗：未来发展趋势如何？
BJU Int. 2008 Feb;101(3):271-4. doi: 10.1111/j.1464-410X.2007.07236.x. Epub 2007 Oct 8.
8
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
9
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.一项随机、双盲研究，比较在非转移性去势抵抗性前列腺癌男性患者中，在GnRH类似物治疗基础上加用比卡鲁胺（无论是否联用度他雄胺）的疗效。
Eur J Cancer. 2015 Aug;51(12):1555-69. doi: 10.1016/j.ejca.2015.04.028. Epub 2015 Jun 2.
10
Recent advances in hormonal therapy for advanced prostate cancer.晚期前列腺癌激素治疗的最新进展
Oncology (Williston Park). 2003 Aug;17(8):1047-52; discussion 1054-8.
引用本文的文献
1
Exploiting pre-dormancy tumor immune microenvironment induced by androgen deprivation in prostate cancer.利用雄激素剥夺诱导的前列腺癌休眠前肿瘤免疫微环境。
Transl Cancer Res. 2025 Apr 30;14(4):2183-2187. doi: 10.21037/tcr-2024-2683. Epub 2025 Apr 15.
2
DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.双膦酸盐与PSMA抑制剂的DOTA偶联物：治疗前列腺癌相关骨转移的一种有前景的联合疗法。
Front Nucl Med. 2022 Jun 29;2:892147. doi: 10.3389/fnume.2022.892147. eCollection 2022.
3
Promoter hypermethylation as a novel regulator of ANO1 expression and function in prostate cancer bone metastasis.启动子超甲基化作为前列腺癌骨转移中ANO1 表达和功能的新型调节因子。
Sci Rep. 2024 May 21;14(1):11595. doi: 10.1038/s41598-024-62478-1.
4
Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.肿瘤细胞乳酸生成信号通路的抑制通过巨噬细胞吞噬作用根除了 PTEN/p53 缺陷的小鼠侵袭性变异前列腺癌。
Clin Cancer Res. 2023 Dec 1;29(23):4930-4940. doi: 10.1158/1078-0432.CCR-23-1441.
5
Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.抑制肿瘤细胞乳酸生成信号通路可通过巨噬细胞吞噬作用根除小鼠PTEN/p53缺陷型侵袭性前列腺癌。
bioRxiv. 2023 May 23:2023.05.23.540590. doi: 10.1101/2023.05.23.540590.
6
Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.让我们进入 3D 时代！新一代模型用于评估前列腺癌中的药物反应和耐药性。
Int J Mol Sci. 2023 Mar 10;24(6):5293. doi: 10.3390/ijms24065293.
7
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.逆转乳酸和 PD-1 介导的巨噬细胞免疫抑制控制 PTEN/p53 缺陷型前列腺癌的生长。
Clin Cancer Res. 2023 May 15;29(10):1952-1968. doi: 10.1158/1078-0432.CCR-22-3350.
8
Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial.低剂量半身放疗：复发性前列腺癌的一种治疗选择——一项2期单臂试验
Adv Radiat Oncol. 2022 Sep 10;8(1):101066. doi: 10.1016/j.adro.2022.101066. eCollection 2023 Jan-Feb.
9
Immunotherapy for prostate cancer: Requirements for a successful regime transfer.前列腺癌的免疫疗法：成功转移方案的要求。
Investig Clin Urol. 2022 Jan;63(1):3-13. doi: 10.4111/icu.20210369.
10
Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies.用于转移性前列腺癌识别与预测的影像组学：研究综述
Front Oncol. 2021 Nov 1;11:771787. doi: 10.3389/fonc.2021.771787. eCollection 2021.
本文引用的文献
1
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.随机、双盲、III 期试验：依匹单抗对比安慰剂在无症状或症状轻微的转移性化疗初治去势抵抗性前列腺癌患者中的应用。
J Clin Oncol. 2017 Jan;35(1):40-47. doi: 10.1200/JCO.2016.69.1584. Epub 2016 Oct 31.
2
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.恩杂鲁胺对比比卡鲁胺用于去势抵抗性前列腺癌：STRIVE 试验。
J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25.
3
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗（STAMPEDE）：一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
4
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
5
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙联合泼尼松对比安慰剂联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌患者（COU-AA-302）：一项随机、双盲、安慰剂对照的 3 期研究的最终总生存分析。
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
6
Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.根治性治疗后前列腺癌局部和远处复发的转移导向治疗：文献系统评价。
Eur Urol. 2015 May;67(5):852-63. doi: 10.1016/j.eururo.2014.09.004. Epub 2014 Sep 17.
7
Enzalutamide in metastatic prostate cancer before chemotherapy.恩杂鲁胺治疗化疗前转移性前列腺癌。
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
8
Evolution of androgen receptor targeted therapy for advanced prostate cancer.雄激素受体靶向治疗晚期前列腺癌的进展。
Nat Rev Clin Oncol. 2014 Jun;11(6):365-76. doi: 10.1038/nrclinonc.2014.72. Epub 2014 May 20.
9
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.依匹木单抗联合放疗对比安慰剂用于多西他赛化疗后进展的转移性去势抵抗性前列腺癌患者（CA184-043）：一项多中心、随机、双盲、III 期临床试验。
Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.
10
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).随机对照试验研究唑来膦酸早期治疗去势敏感性前列腺癌伴骨转移患者的疗效：CALGB 90202（ALLIANCE）研究结果
J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500. Epub 2014 Mar 3.
Zotero 插件